Novosound, the Scottish sensor technology scaleup, has secured a patent for its ultrasonic instrumentation system, with the firm recently launching its related Slanj platform targeted at the medical and wearable device sectors worldwide.

The milestone marks Novosound’s 21st patent awarded since 2018, and gives the company the exclusive rights to sell the technology that has underpinned leading research in Scotland and the United States into wireless, wearable ultrasound.

The company’s CEO and co-founder, Dr Dave Hughes, said: “I’m really proud that Novosound has obtained the first patent for a wearable ultrasound system. This allows us to integrate and license the technology with smartwatch partners, looking deeper into the body and enhancing the measurements their optical and electrical sensors provide, opening up the holy grail of 24/7 blood pressure monitoring on the wrist.”

Novosound is also progressing patent applications for its wearable technology worldwide, while ongoing research and pilot projects—including muscle activity and blood pressure monitoring in smartwatches— are continuing with global tech firms, and also with institutions like the Texas Medical Center.

Hughes added: “This technology builds on the legacy of ultrasound in Scotland, where it was first demonstrated as a medical diagnostic technique at the University of Glasgow in 1954, and now as a Scottish company moves it out of the hospital, into the home via a wearable device.”

The company, which was the University of the West of Scotland’s first ever spinout in 2018, has raised over £10 million since, appointed former Intel executive David Jolliffe as CFO last year, while also announcing commercial contracts with Nasdaq-listed PAVmed Inc., and partnerships at the Texas Medical Center.

The firm is forecasting its fourth year in a row of revenue growth.

Recommended reading

• Novosound Inks New Transatlantic Partnership
• Scots Ultrasound Tech Firm Novosound Appoints New CFO
• Scottish Ultrasound Tech Company Secures £1m to Boost Expansion

The last time DIGIT covered Novosound was on the aforementioned transatlantic partnership with the Texas Medical Center.

Todd Rosengart, vice president and DeBakey board chair of surgery at Baylor College of Medicine, based within the Texas Medical Center in Houston, Texas, said that he’s “been very impressed with the Novosound technology and how we are applying it to a global clinical need, which we believe will save lives and could indeed become the next vital sign monitor.”